 |
78 Diseases |  |
0 Trials |
|
0 Trials |  |
93 News |  |
| «12 |
- ||| Imfinzi (durvalumab) / AstraZeneca, motolimod (VTX 2337) / BMS
Trial initiation date: Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Oct 29, 2015
P1/2, N=53, Not yet recruiting, Sponsor: Ludwig Institute for Cancer Research
Initiation date: Jun 2015 --> Oct 2015
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Trial primary completion date, Combination therapy, Metastases: Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Oct 22, 2015
P2, N=175, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Initiation date: Jun 2015 --> Oct 2015 Trial primary completion date: Sep 2015 --> Sep 2016
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment closed, Combination therapy, Metastases: Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Aug 27, 2015
P2, N=175, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Active, not recruiting
- ||||| Imfinzi (durvalumab) / AstraZeneca, motolimod (VTX 2337) / BMS
New P1/2 trial: Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - May 1, 2015
P1/2, N=53, Not yet recruiting, Sponsor: Ludwig Institute for Cancer Research
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Trial completion, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - Mar 7, 2015
P1, N=13, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - Nov 11, 2014
P1, N=13, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2014
- | motolimod (VTX 2337) / BMS
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (clinicaltrials.gov) - Oct 17, 2014
P1, N=20, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2014 Active, not recruiting --> Completed | N=36 --> 20 | Trial primary completion date: Feb 2015 --> Jul 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, motolimod (VTX 2337) / BMS
Biomarker, Enrollment open, PD(L)-1 Biomarker: A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab (clinicaltrials.gov) - Oct 2, 2014
P1, N=15, Recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Active, not recruiting --> Completed | N=36 --> 20 | Trial primary completion date: Feb 2015 --> Jul 2014 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, motolimod (VTX 2337) / BMS
Biomarker, New P1 trial, PD(L)-1 Biomarker: A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab (clinicaltrials.gov) - Apr 21, 2014
P1, N=15, Not yet recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
- ||| motolimod (VTX 2337) / BMS
Enrollment closed, Combination therapy: VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Apr 13, 2014
P2, N=290, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| motolimod (VTX 2337) / BMS
Enrollment change, Combination therapy: VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 7, 2014
P2, N=290, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Recruiting --> Active, not recruiting N=210 --> 290
- motolimod (VTX 2337) / BMS
Enrollment closed, Combination therapy: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (clinicaltrials.gov) - Jul 17, 2013
P1, N=36, Active, not recruiting, Sponsor: Gynecologic Oncology Group
N=210 --> 290 Recruiting --> Active, not recruiting
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment open, Combination therapy, Metastases: Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 30, 2013
P2, N=175, Recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment change, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - May 28, 2013
P1, N=13, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting N=18 --> 13
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
New P2 trial, Combination therapy, Metastases: Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 17, 2013
P2, N=175, Recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
- ||||| motolimod (VTX 2337) / BMS
New P2 trial, Combination therapy: VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 14, 2012
P2, N=290, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
- motolimod (VTX 2337) / BMS
Trial termination, Combination therapy: VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas (clinicaltrials.gov) - Apr 2, 2012
P1/2, N=2, Terminated, Sponsor: VentiRx Pharmaceuticals Inc.
N=18 --> 13 Recruiting --> Terminated; The study was stopped due to slow rate of recruitment.
- motolimod (VTX 2337) / BMS
Enrollment change, Combination therapy: VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas (clinicaltrials.gov) - Apr 2, 2012
P1/2, N=2, Terminated, Sponsor: VentiRx Pharmaceuticals Inc.
Recruiting --> Terminated; The study was stopped due to slow rate of recruitment. N=15 --> 2
- motolimod (VTX 2337) / BMS
Enrollment change, Combination therapy: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (clinicaltrials.gov) - Mar 22, 2012
P1, N=36, Active, not recruiting, Sponsor: Gynecologic Oncology Group
N=15 --> 2 N=30 --> 36